Blood Cell Patterns Predict Poor Venetoclax Response

TOPLINE:

Erythroid-predominant myelodysplastic neoplasms (EP MDS) (18%) exhibit unique genomic features with frequent TP53 mutations and distinct survival patterns. These cases show poor outcomes with venetoclax therapy due to BCL-XL dependence rather than BCL2 , suggesting the need for alternative treatment strategies.

METHODOLOGY:

Researchers evaluated 371 consecutive patients with newly diagnosed MDS presenting between December 2016 and January 2023, excluding those with chronic myelomonocytic leukemia and acute erythroid leukemia.

A separate cohort of 112 consecutive patients with higher-risk MDS and increased blasts > 5% received hypomethylating agent plus venetoclax therapy between April 2017 and November 2023.

Patients with insufficient, poor, or inadequate bone marrow sa